The limitation of nonendogenous control is also true of the recently published gene therapy strategies for CGD using zinc finger nucleases targeting the AAVS1 safe harbor site for transgene insertion in iPS cells, in which WT copies of the mutant genes are constitutively expressed and, therefore, not myeloid-specific [28,32,33]. Here, PPP1R12C is linked to chronic granulomatous disease.